Salarius Pharmaceuticals, Inc. (Nasdaq:SLRX)
Health Care/Life Sciences • Pharmaceuticals
CIK 1615219
Company
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.
Address
2450 Holcombe Boulevard
Suite X
Houston, Texas 77021
2450 Holcombe Boulevard
Suite X
Houston, Texas 77021
Employees
12
12
Stock Info
Close
$0.6609
$0.6609
Day Range
0.6411 - 0.7069
0.6411 - 0.7069
52 Week Range
0.5000 - 2.6800
0.5000 - 2.6800
Average volume
30.19K
30.19K
Short Interest
18.01K (02/29/24)
18.01K (02/29/24)
% of Float Shorted
0.49%
0.49%
Market Cap
$2.68M
$2.68M
Revenue
N/A
N/A
Net Income
-$31.61M
-$31.61M
2020 Sales Growth
N/A
N/A
Key Executives
Board Of Directors
|
Chairman William K McVicar PhD |
|
Independent Director Jonathan I Lieber MBA |
|
Independent Director Tess Burleson CPA, MBA |
|
Independent Director Bruce J McCreedy PhD |
|
Independent Director Arnold C Hanish CPA |
|
Lead Independent Director Paul Lammers MD |
SEC filings
| Date | Form | Event |
|---|---|---|
| 16 Dec, 2024 | S-1 | |
| 13 Dec, 2024 | 8-K | |
| 14 Nov, 2024 | SC 13G/A | |
| 14 Nov, 2024 | 10-Q | |
| 1 Nov, 2024 | DEF 14A | |
| 1 Nov, 2024 | DEFA14A | |
| 27 Sep, 2024 | 8-K | |
| 15 Aug, 2024 | 8-K | |
| 14 Aug, 2024 | 8-K | |
| 9 Aug, 2024 | 10-Q | |
| 25 Jul, 2024 | 424B5 | |
| 25 Jul, 2024 | 8-K | |
| 23 Jul, 2024 | 8-K | |
| 22 Jul, 2024 | 424B5 | |
| 19 Jul, 2024 | 8-K | |
| 11 Jul, 2024 | 8-K | |
| 17 Jun, 2024 | 8-K | |
| 17 Jun, 2024 | 424B5 | |
| 14 Jun, 2024 | 8-K | |
| 13 May, 2024 | 10-Q | |
| 22 Apr, 2024 | 10-K/A | |
| 12 Apr, 2024 | 4 | |
| 26 Mar, 2024 | DEF 14A | |
| 26 Mar, 2024 | DEFA14A | |
| 22 Mar, 2024 | 10-K | |
| 20 Mar, 2024 | DFAN14A | |
| 15 Mar, 2024 | PRE 14A | |
| 6 Mar, 2024 | 8-K | |
| 23 Feb, 2024 | 8-K | CEO Change |
| 22 Feb, 2024 | 4 | |
| 22 Feb, 2024 | 4 | |
| 22 Feb, 2024 | 4 | |
| 22 Feb, 2024 | 4 | |
| 22 Feb, 2024 | 4 | |
| 22 Feb, 2024 | 4 | |
| 22 Feb, 2024 | 4 | |
| 14 Feb, 2024 | SC 13G | |
| 9 Nov, 2023 | 10-Q | |
| 27 Oct, 2023 | SC 13D | |
| 6 Sep, 2023 | 8-K | |
| 10 Aug, 2023 | 10-Q | |
| 10 Aug, 2023 | 8-K | |
| 12 Jul, 2023 | 8-K | |
| 15 Jun, 2023 | 8-K | |
| 7 Jun, 2023 | 424B3 | |
| 6 Jun, 2023 | EFFECT | |
| 2 Jun, 2023 | CORRESP | |
| 1 Jun, 2023 | S-3/A | |
| 1 Jun, 2023 | UPLOAD | |
| 26 May, 2023 | S-3 | |
| 25 May, 2023 | D | |
| 16 May, 2023 | 8-K | |
| 11 May, 2023 | 10-Q | |
| 1 May, 2023 | DEF 14A | |
| 1 May, 2023 | DEFA14A | |
| 27 Mar, 2023 | 10-K | |
| 13 Mar, 2023 | 8-K | |
| 15 Feb, 2023 | 4 | |
| 15 Feb, 2023 | S-8 | |
| 15 Feb, 2023 | 4 | |
| 13 Feb, 2023 | SC 13G/A | |
| 10 Jan, 2023 | 8-K | |
| 5 Jan, 2023 | 4 | |
| 5 Jan, 2023 | 4 | |
| 5 Jan, 2023 | 4 | |
| 5 Jan, 2023 | 4 | |
| 5 Jan, 2023 | 4 | |
| 5 Jan, 2023 | 4 | |
| 5 Jan, 2023 | 4 | |
| 5 Jan, 2023 | 4 | |
| 12 Dec, 2022 | 4/A | |
| 12 Dec, 2022 | 4/A | |
| 1 Dec, 2022 | 8-K | |
| 10 Nov, 2022 | 8-K | |
| 10 Nov, 2022 | 10-Q | |
| 8 Nov, 2022 | 4/A | |
| 8 Nov, 2022 | 4/A | |
| 7 Nov, 2022 | 4 | |
| 7 Nov, 2022 | 4 | |
| 3 Nov, 2022 | 8-K | |
| 27 Oct, 2022 | 8-K | |
| 18 Oct, 2022 | 8-K | |
| 14 Oct, 2022 | 8-K | |
| 16 Aug, 2022 | EFFECT | |
| 15 Aug, 2022 | 8-K | |
| 12 Aug, 2022 | CORRESP | |
| 10 Aug, 2022 | UPLOAD | |
| 5 Aug, 2022 | 10-Q | |
| 5 Aug, 2022 | S-3 | |
| 3 Aug, 2022 | 8-K | |
| 23 Jun, 2022 | EFFECT | |
| 21 Jun, 2022 | UPLOAD | |
| 21 Jun, 2022 | CORRESP | |
| 17 Jun, 2022 | 8-K | |
| 10 Jun, 2022 | S-3 | |
| 8 Jun, 2022 | 4 | |
| 8 Jun, 2022 | 4 | |
| 7 Jun, 2022 | 4 | |
| 6 Jun, 2022 | 4/A | |
| 6 Jun, 2022 | 4/A | |
| 6 Jun, 2022 | 4/A | |
| 6 Jun, 2022 | 4 | |
| 31 May, 2022 | 4 | |
| 31 May, 2022 | 4 | |
| 12 May, 2022 | 10-Q | |
| 12 May, 2022 | 8-K | |
| 12 May, 2022 | DEFA14A | |
| 9 May, 2022 | UPLOAD | |
| 6 May, 2022 | CORRESP | |
| 5 May, 2022 | 4 | |
| 29 Apr, 2022 | SC 13G | |
| 28 Apr, 2022 | DEF 14A | |
| 28 Apr, 2022 | DEFA14A | |
| 27 Apr, 2022 | SC 13G | |
| 26 Apr, 2022 | 424B5 | |
| 26 Apr, 2022 | 8-K | |
| 22 Apr, 2022 | 8-K | |
| 22 Apr, 2022 | UPLOAD | |
| 15 Apr, 2022 | PRE 14A | |
| 1 Apr, 2022 | 8-K | |
| 25 Mar, 2022 | 10-K | |
| 10 Mar, 2022 | 8-K | |
| 9 Mar, 2022 | 4 | |
| 9 Mar, 2022 | 4 | |
| 22 Feb, 2022 | S-8 | |
| 10 Feb, 2022 | SC 13G/A | |
| 21 Jan, 2022 | 4 | |
| 21 Jan, 2022 | 4 | |
| 21 Jan, 2022 | 4 | |
| 21 Jan, 2022 | 4 | |
| 21 Jan, 2022 | 4 | |
| 21 Jan, 2022 | 4 | |
| 21 Jan, 2022 | 4 | |
| 21 Jan, 2022 | 4 | |
| 13 Jan, 2022 | 8-K | |
| 19 Nov, 2021 | 8-K | |
| 5 Nov, 2021 | 4 | |
| 5 Nov, 2021 | 4 | |
| 4 Nov, 2021 | 10-Q | |
| 16 Sep, 2021 | 8-K | |
| 20 Aug, 2021 | 8-K | |
| 17 Aug, 2021 | 4 | |
| 11 Aug, 2021 | 4 | |
| 5 Aug, 2021 | 10-Q | |
| 5 Aug, 2021 | 8-K | |
| 2 Jul, 2021 | 424B5 | |
| 2 Jul, 2021 | 8-K | |
| 1 Jul, 2021 | 8-K | |
| 1 Jul, 2021 | 424B5 | |
| 16 Jun, 2021 | 8-K | |
| 20 May, 2021 | 8-K | |
| 12 May, 2021 | 8-K | |
| 12 May, 2021 | 10-Q | |
| 5 May, 2021 | 4 | |
| 5 May, 2021 | 4 | |
| 27 Apr, 2021 | DEFA14A | |
| 27 Apr, 2021 | DEF 14A | |
| 18 Mar, 2021 | 10-K | |
| 8 Mar, 2021 | 8-K | |
| 5 Mar, 2021 | 424B5 | |
| 3 Mar, 2021 | 424B5 | |
| 3 Mar, 2021 | 8-K | |
| 17 Feb, 2021 | 8-K | |
| 16 Feb, 2021 | SC 13G/A | |
| 16 Feb, 2021 | SC 13G | |
| 12 Feb, 2021 | SC 13G/A | |
| 5 Feb, 2021 | 8-K | |
| 5 Feb, 2021 | 424B5 | |
| 1 Feb, 2021 | EFFECT | |
| 28 Jan, 2021 | SC 13G/A | |
| 28 Jan, 2021 | CORRESP | |
| 21 Jan, 2021 | 8-K | |
| 20 Jan, 2021 | UPLOAD | |
| 15 Jan, 2021 | S-3 |
Last update:2024-03-12 12:01:33.493093
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.